Additive clinical value of serum brain-derived neurotrophic factor for prediction of chronic heart failure outcome

• Published in: Heart and vessels Vol. 31; no. 4; pp. 535 - 544
• Main Authors: Kadowaki, Shinpei, Shishido, Tetsuro, Honda, Yuki, Narumi, Taro, Otaki, Yoichiro, Kinoshita, Daisuke, Nishiyama, Satoshi, Takahashi, Hiroki, Arimoto, Takanori, Miyamoto, Takuya, Watanabe, Tetsu, Kubota, Isao
• Format: Journal Article
• Language: English
• Published: Tokyo Springer Japan 01.04.2016; Springer Nature B.V
• Subjects: Aged; Biomarkers - blood; Biomedical Engineering and Bioengineering; Brain-derived neurotrophic factor; Brain-Derived Neurotrophic Factor - blood; Cardiac Surgery; Cardiology; Disease Progression; Echocardiography; Enzyme-Linked Immunosorbent Assay; Female; Heart failure; Heart Failure - blood; Heart Failure - diagnosis; Heart Failure - epidemiology; Heart Ventricles - diagnostic imaging; Humans; Incidence; Japan - epidemiology; Kaplan-Meier Estimate; Male; Medical prognosis; Medicine; Medicine & Public Health; Original Article; Prognosis; Radiography, Thoracic; Retrospective Studies; Risk Factors; ROC Curve; Survival Rate - trends; Vascular Surgery; Heart failure; Brain-derived neurotrophic factor; Prognosis; Risk stratification
• ISSN: 0910-8327; 1615-2573; 1615-2573
• DOI: 10.1007/s00380-015-0628-6

The importance of the central nervous system in cardiovascular events has been recognized. Recently, brain-derived neurotrophic factor (BDNF), a member of the neurotrophic factor family, is involved in depression mechanisms and also in stress and anxiety. Because BDNF is reported about cardioprotective role, we elucidated whether BDNF is associated with cardiovascular events in patients with chronic heart failure (CHF). We examined serum BDNF levels in 134 patients with CHF and 23 control subjects. The patients were followed to register cardiac events for a median of 426 days. BDNF was significantly lower in CHF patients than in control subjects (25.8 ± 8.4 vs 14.7 ± 8.4, P  < 0.0001). Serum BDNF was also lower in patients with cardiac events than in event-free patients (16.1 ± 8.0 vs 12.5 ± 8.5, P  < 0.0001). The cutoff value of BDNF was determined by performing receiver operating characteristic curve analysis. Kaplan–Meier analysis demonstrated that patients with low levels of BDNF experienced higher rates of cardiac events than those with high levels of BDNF. Multivariate Cox hazard analysis demonstrated that low BDNF levels (≤12.4 ng/mL) were an independent prognostic factor for cardiac events (hazard ratio 2.932, 95 % confidence interval 1.622–5.301; P  = 0.0004). Adding levels of BDNF to the model with BNP levels, age, and eGFR for the prediction of cardiac events yielded significant net reclassification improvement of 0.429 ( P  < 0.001) and an integrated discrimination improvement of 0.101 ( P  < 0.001). Low serum BDNF levels were found in patients with CHF, and these levels were found to be independently associated with an increased risk of cardiac events.